Overview

Effects of Pioglitazone in Calcific Aortic Valve Disease

Status:
Not yet recruiting
Trial end date:
2028-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, comparative, clinical trial conducted by Wuhan Union Hospital that aims to evaluate the efficacy and safety of pioglitazone compared to placebo in patients with calcific aortic valve disease with mild aortic valve stenosis.
Phase:
Phase 2
Details
Lead Sponsor:
Wuhan Union Hospital, China
Treatments:
Pioglitazone